Background
Chronic obstructive pulmonary disease (COPD) is a highly prevalent, non-curable, life-threatening disease, characterised by irreversible changes in lung structures [
1‐
3]. Pulmonary vascular abnormalities, as shown by alterations in vessel structure, abnormal cell growth, endothelial dysfunction and resistance to apoptosis, are characteristic features in COPD [
4,
5]. An altered pulmonary vascular function in COPD patients may predispose to pulmonary hypertension, which is associated with adverse outcomes [
6]. Growing evidence suggests that endothelial cell damage found in pulmonary vessels of COPD patients is an initial and important triggering factor that promotes pulmonary vascular remodelling [
5]. It has been shown that COPD patients present endothelial dysfunction in both pulmonary and systemic arteries at early disease stages [
7‐
9]. This endothelial damage may result from an imbalance between vascular injury and the body’s repair capacity [
10].
Bone marrow-derived progenitor cells (PCs) are a population of rare, pre-differentiated adult stem cells that circulate in the blood with the ability to proliferate and differentiate into mature endothelial cells [
11]. Although, the contribution of PCs in vascular remodelling and repair is unclear, it is believed that under pathological conditions, PCs are mobilized from the bone marrow and recruited to sites of vascular injury to maintain vascular homeostasis [
7]. PCs are believed to be essential in maintenance of the endothelium’s integrity and restoration of normal function, replacing terminally differentiated cells lost as a consequence of physiological cell turnover or tissue damage [
12]. Conversely, it has also been suggested that in COPD, PCs mobilization and recruitment may contribute to COPD pathogenesis. PCs intrinsic dysfunctional activity, mainly due to cigarette smoke (CS) exposure, promotes inflammation, pulmonary vessel remodelling and pulmonary hypertension [
13].
Reduced number and function of circulating PCs has been established as an independent prognostic factor associated with endothelial dysfunction, high cardiovascular risk and increased mortality [
14‐
16]. In COPD, few studies to date have investigated the number of circulating PCs [
10,
12,
17]. We and others have previously shown reduced levels of circulating PCs in COPD patients, as compared to controls [
10,
12,
17]. To date, two different mechanisms have been suggested to explain the reduced number of circulating PCs seen in COPD, an impairment of the bone marrow to generate enough circulating PC numbers and/or an increased PC recruitment in pulmonary vessels in response to tissue injury. Accordingly, in this study we aimed to quantify in the same individuals both circulating PCs and bone marrow-derived cells localized in pulmonary arteries, as well as their association to pulmonary artery remodelling, and systemic and pulmonary artery functionality.
Discussion
The present study shows that in COPD the decrease of circulating PCs is associated with the presence of bone marrow-derived cells in pulmonary arteries and the number of CD45+ cells infiltrating the intima of pulmonary arteries directly correlated with pulmonary vascular remodelling.
Circulating CD45
+CD34
+CD133
+ PCs were significantly reduced in COPD patients compared with the non-COPD group, confirming recent findings published by our group and others [
10,
12,
17]. Reduced number of circulating PCs has been established as a prognostic risk factor associated with endothelial dysfunction and increased cardiovascular risk [
14]. PCs residing in the bone marrow under homeostatic conditions can be mobilized into the circulation in response to tissue damage and are believed to be essential in tissue regeneration replacing terminally differentiated cells lost because of physiological cell turnover or tissue damage [
10].
The role of PCs in COPD and tissue regeneration is not fully understood, and different mechanisms have been suggested to explain the reduced number of circulating PCs seen in COPD patients. One potential explanation is an increased recruitment of these cells to sites of tissue injury, namely in the pulmonary vasculature. Tissue repair and regeneration following injury is thought to involve resident cell proliferation as well as a selective recruitment of circulating progenitor cell populations through complex signalling cascades [
24]. Our group has previously shown an increased number of CD133
+ progenitor cells localized in the wall of pulmonary arteries of COPD patients [
22]. Similarly, in this study a significant number of CD133
+ progenitor cells localized within the pulmonary artery of COPD patients suggesting their involvement in pulmonary vessel repair mechanisms.
In the present study, we extend these previous findings and show that COPD patients present a greater number of CD45+ cells in pulmonary arteries than non-COPD subjects. Interestingly, the number of CD45+ cells within the pulmonary artery wall was inversely correlated with the number of circulating CD45+CD34+CD133+ cells, patients with lower number of circulating PCs had a higher number of CD45+ cells in the vessel wall. Although this correlation does not establish a cause and effect relationship, it is plausible that in COPD, progenitor cell mobilization and homing in pulmonary arteries may occur in response to vascular damage, causing the depletion of the pool of circulating PCs.
Exposure to CS is the primary cause of COPD and plays a key role in PC dysfunction [
25]. Dysfunctional PCs show excessive apoptosis and are unable to respond to external injuries to mediate proper lung tissue healing [
26]. Previous results from our group showed in an experimental animal model, that short-term exposure to CS induced PCs dysfunction, affecting pulmonary homing and proliferation [
27]. In vitro, CS altered the rate of proliferation, senescence, differentiation and migration capacity of PCs [
27]. In COPD patients, dysfunctional PCs may be unable to support the normal repair of the pulmonary vasculature promoting neointima formation, vessel remodelling and disease progression. In line with these results, our group has previously shown that bone marrow derived CD133
+ cells had the capacity to migrate from the vessel lumen into the intima and differentiate into smooth muscle cells, exerting remodelling effects on injured vessels [
28].
In the present study, COPD patients displayed thicker pulmonary artery walls and reduced lumens than non-COPD subjects. Interestingly, the increased number of CD45
+ cells localized in the pulmonary artery wall was associated with a reduction in the arterial lumen. This is in agreement with previous observations from our group showing that structural alterations in pulmonary arteries occur at early stages in COPD and that the number of CD133
+ cells attached to the endothelium was greater in COPD patients than in control subjects [
23]. Overall, the current and previous findings suggest a potential causative role of progenitor cell recruitment in the pathogenesis of pulmonary vascular remodelling in COPD.
COPD patients and non-COPD subjects showed similar values of systemic endothelial function, though both groups had lower values than those previously observed in healthy non-smokers [
17]. This indicates that both COPD patients and non-COPD subjects in this study presented systemic endothelial dysfunction. We have previously reported significant differences in FMD values between control non-smokers and both COPD patients and smokers without COPD [
17]. Accordingly, the reduced value of FMD shown herein in the non-COPD group is likely due to the fact that most of the non-COPD subjects were heavy smokers. When the non-COPD group was divided in non-smokers and smokers a marked increase of FMD was seen in the non-smoker group compared to the smoker control group. We also observed that FMD values were unrelated to the number of circulating PCs or CD45
+ cells localized in the pulmonary artery wall. This agrees with previous findings where no significant correlation was found between the number of circulating PCs and FMD values between COPD and non-COPD subjects [
17].
Endothelium-dependent dilation and distensibility values measured in isolated pulmonary arteries were reduced in COPD patients compared to non-COPD subjects and correlated with the number of infiltrating CD45+ cells in pulmonary arteries. This is consistent with the notion that impairment of the endothelial function in pulmonary arteries may promote the mobilization and homing of bone marrow-derived PCs. Systemic endothelial dysfunction did not correlate with pulmonary endothelial dysfunction. We consider that endothelial dysfunction in systemic arteries is more likely due to chronic CS exposure rather than a systemic effect of COPD. On the other hand, pulmonary endothelial dysfunction appears to be more directly related to progenitor cell homing in response to injury and vessel remodelling. Overall, these findings suggest that CS might exert direct effects on endothelial function in both systemic and pulmonary arteries, irrespective of the number of recruited PCs in remodelled pulmonary arteries.
DLco values were not associated with variations in the number of circulating PCs or bone marrow-derived cells recruited in pulmonary vessels. Yet, lower DLco values were associated with greater remodelling of pulmonary arteries. Neither the severity of airflow obstruction nor the values of PaO2, were related to changes in PCs or pulmonary vascular remodelling. Overall, our findings are in line with the notion that DLco is a marker of pulmonary vascular integrity. Finally, non-COPD controls were separated in non-smokers and smokers and compared to COPD patients. In most parameters analyzed, non-COPD smokers presented an intermediate phenotype between non-smoker controls and COPD subjects indicating the key role of CS exposure in lung and endothelial dysfunction.
The main strength of this study was the simultaneous measurement of markers of vascular integrity and function in both systemic and pulmonary arteries, using lung tissue samples, in the same individual. Nevertheless, our study has some limitations. First, the reduced number of subjects, which is inherent to the need to evaluate patients undergoing lung resection in whom the lung neoplasm was localized and did not produce changes in lung parenchyma or respiratory function. Second, the CD45 maker used in tissue assessment is not specific to progenitor cells and could also indicate recruitment of other cell populations. Further studies using double staining for both CD133 and CD45 immunofluorescence are required to prove that these migrated cells in the intima of the pulmonary arteries are derived from circulating PCs. Third, in this study we could not be certain that the number of CD45+ cells present in the pulmonary walls and the reduced artery lumen area, were directly associated to the reduced number of circulating CD45+CD34+CD133+ cells in these patients. However, the direct correlation between the number of circulating CD45+CD34+CD133+ cells and the number of CD45+ infiltrates in pulmonary vessels and the presence of CD133+ cells, an intrinsic marker of progenitor cells, observed in the vessel wall might infer that in COPD patients, circulating CD45+CD34+CD133+ cells are recruited in response to injury to the pulmonary vessel wall, causing a reduction in circulating PCs numbers.
Interestingly, recent data suggested the existence of a “vasculogenic zone” in the wall of human blood vessels, which might serve as a reservoir for PCs capable to differentiate into mature endothelial cells [
29]. Accordingly, the presence of PCs recruited as a result of an injury response could not solely be explained by the homing of bone-marrow derived circulating PCs as tissue resident PCs could also play an important role. Finally, some of the results are represented as correlations and therefore only describe an association, they do not prove a cause and effect relationship.